Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 3:36 AM ET


Company Overview of Oxford Gene Technology IP Limited

Company Overview

Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...

Begbroke Science Park

Begbroke Hill

Woodstock Road

Begbroke,  OX5 1PF

United Kingdom

Founded in 1995


44 1865 856800


44 1865 848684

Key Executives for Oxford Gene Technology IP Limited

Chief Executive Officer
Age: 57
Founder, Chief Science Advisor and Director
Chief Financial Officer
Age: 52
Executive Vice President of Oxford Operations
Executive Vice President of Sales
Compensation as of Fiscal Year 2015.

Oxford Gene Technology IP Limited Key Developments

Oxford Gene Technology Reports Revenue Results for the Fiscal 2015

Oxford Gene Technology reported revenue results for the fiscal 2015. Total revenue grew by 12% to £17.1 million despite divestments and anticipated fall in royalty income.

Oxford Gene Technology Launches New Arrays for Developmental Disorders at European Society of Human Genetics

Oxford Gene Technology (OGT) launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders (DDD) study data which successfully identified new areas of the genome responsible for developmental disorders. 1, 2 OGT has used this data, together with the latest updates from ClinGen, to deliver the most advanced, high-resolution developmental disorder arrays currently available. OGT has optimised the arrays through a proprietary probe design algorithm and experimental validation, enabling the selection of highly-targeted, specific probes throughout the genome. Using an informed, sophisticated approach to array design, more of these optimised probes have been placed in regions of the genome that are most likely to detect a biologically relevant aberration. The result of this careful design procedure means that regions with the high priority are covered at exon-level resolution on the arrays, enabling single-exon CNV detection in up to 502 prioritized genes of interest. Providing straightforward analysis, all CytoSure arrays come with OGT’s renowned Cytosure Interpret Software and full on-site training, streamlining data analysis and interpretation. Innovative features enable the automation of data analysis workflows, minimizing user intervention and maximizing both consistency and speed of interpretation.

Oxford Gene Technology Gets £1.2 Million Genomics England Contract

Oxford Gene Technology (OGT) announced that it has been awarded a £1.2 million phase two Small Business Research Initiative (SBRI) Healthcarecontract. The contract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK. Development of this innovative technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically relevant results. These easy to understand reports will support faster diagnosis and better patient care.

Similar Private Companies By Industry

Company Name Region
Marine Biotech Limited Europe
Biological Preparations Ltd Europe
GeneForm Technologies Ltd. Europe
Neurotex Limited Europe
Isogenica Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oxford Gene Technology IP Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at